A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models.

Simple Summary: Podoplanin (PDPN), also known as T1α/Aggrus/gp36, is a type I transmembrane sialo-glycoprotein that plays essential roles in cancer progression and metastasis. PDPN-expressing cancers show aggressive phenotypes, including increased stemness, invasiveness, and epithelial-to-mesenchymal transition, which lead to malignant progression. Furthermore, PDPN-positive cancer-associated fibroblasts mediate an immunosuppressive tumor microenvironment, which reduces antitumor immunity. Therefore, monoclonal antibodies (mAbs) against PDPN have been evaluated in preclinical models. In this study, we developed a humanized and defucosylated mAb against PDPN (humLpMab-23-f) and evaluated its antibody-dependent cellular cytotoxicity (ADCC) and antitumor effect in xenograft models of human tumor cells. humLpMab-23-f exerted antitumor activity against PDPN-overexpressed CHO-K1, endogenous PDPN-positive PC-10 (human lung squamous cell carcinoma), and LN319 (human glioblastoma) xenograft-inoculated mice. A cancer-specific anti-PDPN mAb, LpMab-23 (mouse IgG1, kappa), was established in our previous study. We herein produced a humanized IgG1 version (humLpMab-23) and defucosylated form (humLpMab-23-f) of an anti-PDPN mAb to increase ADCC activity. humLpMab-23 recognized PDPN-overexpressed Chinese hamster ovary (CHO)-K1 (CHO/PDPN), PDPN-positive PC-10 (human lung squamous cell carcinoma), and LN319 (human glioblastoma) cells via flow cytometry. We then demonstrated that humLpMab-23-f induced ADCC and complement-dependent cytotoxicity against CHO/PDPN, PC-10, and LN319 cells in vitro and exerted high antitumor activity in mouse xenograft models, indicating that humLpMab-23-f could be useful as an antibody therapy against PDPN-positive lung squamous cell carcinomas and glioblastomas. [ABSTRACT FROM AUTHOR]